Stéphane BIRKLE

Prof. Stéphane BIRKLE

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NRNidia ALVAREZ RUEDA
Nidia ALVAREZ RUEDA
ADAriane Desselle
Ariane Desselle
DCDenis Cochonneau
Denis Cochonneau
TCTanguy Chaumette
Tanguy Chaumette
BCBéatrice Clemenceau
Béatrice Clemenceau
SBStéphane BIRKLE
Stéphane BIRKLE
Monoclonal antibodies (mAb) against GD2 ganglioside have been shown to be effective for the treatment of neuroblastoma. Beneficial actions are, however, associated with generalized pain due to the binding of anti- GD2 mAbs to peripheral nerve fibers followed by complement activation. Neuroblastoma cells that express GD2 also express its O-acetyl derivative, O-acetyl- GD2 ganglioside (OAcGD2). Hence, we investigated the distribution of OAcGD2 in human tissues using mAb 8B6 to study the cross-reactivity of mAb 8B6 with human tissues. The distribution of OAcGD2 was performed in normal and malignant tissues using an immunoperoxydase technique. Anti-tumor properties of mAb 8B6 were studied in vitro and in vivo in a transplanted tumor model in mice. We found that OAcGD2 is not expressed by peripheral nerve fibers. Furthermore, we demonstrated that mAb 8B6 was very effective in the in vitro and in vivo suppression of the growth of tumor cells. Importantly, mAb 8B6 anti-tumor efficacy was comparable to that of mAb 14G2a specific to GD2. Development of therapeutic antibodies specific to OAcGD2 may offer treatment options with reduced adverse side effects, thereby allowing dose escalation of antibodies.

1 March 2007 in Molecular Immunology
Verified
Journal Article
Closed access
NRNidia ALVAREZ RUEDA
Nidia ALVAREZ RUEDA
GBGhislaine Behar
Ghislaine Behar
VFVirginie Ferré
Virginie Ferré
MPMartine Pugnière
Martine Pugnière
FRFrançoise Roquet
Françoise Roquet
SBStéphane BIRKLE
Stéphane BIRKLE

21 August 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PMPierre Machy
Pierre Machy
EMErwan Mortier
Erwan Mortier
SBStéphane BIRKLE
Stéphane BIRKLE
Part of the broader glycosphingolipid family, gangliosides are composed of a ceramide bound to a sialic acid-containing glycan chain, and locate at the plasma membrane. Gangliosides are produced through sequential steps of glycosylation and sialylation. This diversity of composition is reflected in differences in expression patterns and functions of the various gangliosides. Ganglioside GD2 designates different subspecies following a basic structure containing three carbohydrate residues and two sialic acids. GD2 expression, usually restrained to limited tissues, is frequently altered in various neuroectoderm-derived cancers. While GD2 is of evident interest, its glycolipid nature has rendered research challenging. Physiological GD2 expression has been linked to developmental processes. Passing this stage, varying levels of GD2, physiologically expressed mainly in the central nervous system, affect composition and formation of membrane microdomains involved in surface receptor signaling. Overexpressed in cancer, GD2 has been shown to enhance cell survival and invasion. Furthermore, binding of antibodies leads to immune-independent cell death mechanisms. In addition, GD2 contributes to T-cell dysfunction, and functions as an immune checkpoint. Given the cancer-associated functions, GD2 has been a source of interest for immunotherapy. As a potential biomarker, methods are being developed to quantify GD2 from patients’ samples. In addition, various therapeutic strategies are tested. Based on initial success with antibodies, derivates such as bispecific antibodies and immunocytokines have been developed, engaging patient immune system. Cytotoxic effectors or payloads may be redirected based on anti-GD2 antibodies. Finally, vaccines can be used to mount an immune response in patients. We review here the pertinent biological information on GD2 which may be of use for optimizing current immunotherapeutic strategies.

10 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MTMickaël Terme
Mickaël Terme
MDMylène Dorvillius
Mylène Dorvillius
DCDenis Cochonneau
Denis Cochonneau
TCTanguy Chaumette
Tanguy Chaumette
WXWenhua Xiao
Wenhua Xiao
SBStéphane BIRKLE
Stéphane BIRKLE
Anti-GD2 antibody is a proven therapy for GD2-postive neuroblastoma. Monoclonal antibodies against GD2, such as chimeric mAb ch14.18, have become benchmarks for neuroblastoma therapies. Pain, however, can limit immunotherapy with anti-GD2 therapeutic antibodies like ch14.18. This adverse effect is attributed to acute inflammation via complement activation on GD2-expressing nerves. Thus, new strategies are needed for the development of treatment intensification strategies to improve the outcome of these patients. We established the mouse-human chimeric antibody c.8B6 specific to OAcGD2 in order to reduce potential immunogenicity in patients and to fill the need for a selective agent that can kill neuroblastoma cells without inducing adverse neurological side effects caused by anti-GD2 antibody immunotherapy. We further analyzed some of its functional properties compared with anti-GD2 ch14.18 therapeutic antibody. With the exception of allodynic activity, we found that antibody c.8B6 shares the same anti-neuroblastoma attributes as therapeutic ch14.18 anti-GD2 mAb when tested in cell-based assay and in vivo in an animal model. The absence of OAcGD2 expression on nerve fibers and the lack of allodynic properties of c.8B6–which are believed to play a major role in mediating anti-GD2 mAb dose-limiting side effects–provide an important rationale for the clinical application of c.8B6 in patients with high-risk neuroblastoma.

9 May 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JFJulien Fleurence
Julien Fleurence
DCDenis Cochonneau
Denis Cochonneau
SFSophie Fougeray
Sophie Fougeray
LOLisa Oliver
Lisa Oliver
FGFanny Geraldo
Fanny Geraldo
SBStéphane BIRKLE
Stéphane BIRKLE
Targeting and killing glioblastoma with monoclonal antibody to O -acetyl GD2 ganglioside

1 January 2017 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
JFJulien Fleurence
Julien Fleurence
SFSophie Fougeray
Sophie Fougeray
MBMeriem Bahri
Meriem Bahri
DCDenis Cochonneau
Denis Cochonneau
BCBéatrice Clémenceau
Béatrice Clémenceau
SBStéphane BIRKLE
Stéphane BIRKLE
Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application.O-Acetyl-GD2, theO-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role ofO-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance ofO-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included.